BONUSCAP-ZERTIFIKAT - NOVO-NORDISK B | Real-time BOERSE MUENCHEN 20:45:08 31/05/2024 BST | ||
| 891.6 EUR | -0.01% |
|
| 1 month | +0.30% | ||
| 3 months | +1.15% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 891.6 | -0.01% |
| 30/05/24 | 891.7 | +0.03% |
| 29/05/24 | 891.4 | +0.00% |
| 28/05/24 | 891.4 | +0.01% |
| 27/05/24 | 891.3 | +0.01% |
Real-time BOERSE MUENCHEN
Last update May 31, 2024 at 08:45 pm
More quotesStatic data
| Product type | Bonus- and Part-Guarantee-Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
UniCredit
|
| WKN | HD0CGQ |
| ISIN | DE000HD0CGQ6 |
| Date issued | 01/11/2023 |
| Strike | 900 kr |
| Maturity | 20/09/2024 (110 Days) |
| Parity | 1 : 1 |
| Emission price | 826.6 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 892.1 € |
|---|---|
| Lowest since issue | 816.9 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Certificates
- Certificat
